Moderna

Moderna is charging between $32 to $37 per dose for its coronavirus vaccine for some customers, under cheaper "pandemic pricing," it said Wednesday.The Cambridge, Massachusetts-based company is currently in discussion for larger volume agreements that will have a lower price, Moderna CEO Stephane Bancel said on a conference call discussing the company's second-quarter financial results. "We are…

By Carl O'DonnellJuly 27 (Reuters) - Moderna Inc and Pfizer Inc launched two 30,000-subject trials of COVID-19 vaccines that could clear the way for regulatory approval and widespread use by the end of this year, the companies said on Monday.The trials, both announced on Monday, are the first late-stage studies supported by the Trump administration's…

This biotech company is hard at work to win the coronavirus vaccine race. Will it succeed? All eyes are on the drug manufacturers that are racing to develop the first safe and efficacious coronavirus vaccine. Global COVID-19 cases have crossed the 15 million mark, with at least 634,000 deaths worldwide. In the United States alone,…

Moderna’s phase 1 data looks positive, but the company’s investigational coronavirus vaccine has a lot more to prove in late-stage trials. Moderna (NASDAQ:MRNA) has taken another step closer to making its dream of commercializing a coronavirus vaccine a reality. The company just released more detailed interim results from its phase 1 trial -- and they…

Published: July 14, 2020 at 6:23 p.m. ET New study shows ‘robust’ immune response to trial vaccine, Moderna says Moderna headquarters in Cambridge, Mass. Getty Images Moderna Inc. stock skyrocketed in the extended session Tuesday after the biotech company said its coronavirus vaccine candidate produced a “robust” immune-system response in a larger group of people…